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Abstract
Helicobacter pylori (H. pylori) is a major human pathogen causing chronic gastritis, peptic ulcer, gastric cancer, and mucosa-
associated lymphoid tissue lymphoma. One of the mechanisms whereby it induces damage depends on its interference
with proliferation of host tissues. We here describe the discovery of a novel bacterial factor able to inhibit the cell-cycle of
exposed cells, both of gastric and non-gastric origin. An integrated approach was adopted to isolate and characterise the
molecule from the bacterial culture filtrate produced in a protein-free medium: size-exclusion chromatography, non-
reducing gel electrophoresis, mass spectrometry, mutant analysis, recombinant protein expression and enzymatic assays. L-
asparaginase was identified as the factor responsible for cell-cycle inhibition of fibroblasts and gastric cell lines. Its effect on
cell-cycle was confirmed by inhibitors, a knockout strain and the action of recombinant L-asparaginase on cell lines.
Interference with cell-cycle in vitro depended on cell genotype and was related to the expression levels of the concurrent
enzyme asparagine synthetase. Bacterial subcellular distribution of L-asparaginase was also analysed along with its
immunogenicity. H. pylori L-asparaginase is a novel antigen that functions as a cell-cycle inhibitor of fibroblasts and gastric
cell lines. We give evidence supporting a role in the pathogenesis of H. pylori-related diseases and discuss its potential
diagnostic application.
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Introduction
Helicobacter pylori is a common human pathogen that colonizes
the gastric mucosa and induces DNA damage, chronic gastritis,
peptic ulcer, gastric cancer, and mucosa-associated lymphoid tissue
lymphoma of the stomach (class I carcinogen) [1]. Development
of adenocarcinoma of the distal stomach in humans [2,3] and in
experimental animals [4,5] has been associated with infection by
the bacterium. There is experimental evidence demonstrating that
stimulation of epithelial cell proliferation and increased apoptotic
cell death [5–14] are among the pathogenetic processes involved
in H. pylori’s associated diseases, which suggests that the bacterium
could interfere with the maintenance of the integrity of the
gastric mucosa and even favour tumour formation by affecting
the normal balance between epithelial cell proliferation and cell
death. In vitro studies where cultured cells were exposed to whole
bacteria, bacterial lysates or broth culture filtrate, showed both
increased [15] and decreased [16–20] cell proliferation, thus point-
ing to differential effects exerted by bacterial products on different
cell lines.
In previous work we have shown that H. pylori bacterial broth
culture filtrate (BCF) can induce cell-cycle arrest (G1 phase) in
several cell lines in a vacuolating cytotoxin A (VacA), cytotoxin-
associated gene A (CagA) and Urease-independent manner [21].
This evidence suggested that one or more unknown bacterial
factors could have an important role in this process and prompted
us to pursue its/their isolation.
The cell cycle of normal human fibroblasts (HDF) was
particularly affected by BCF compared to other cell lines [21],
thus they were selected as a reference model throughout this study.
These cells are an interesting experimental system for several
reasons: in vivo they are present in the subepithelial mucosa and
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13892can be a target of bacterial factors leaking through epithelial
lesions or transferred there through the epithelium [22]; they
participate in the immune response behaving as reactive tissue
components, initiating the earliest molecular events of the
inflammatory response [23], and also acting as antigen presenting
cells. In this respect, we have previously demonstrated that
interference with their function can potentially have profound
consequences for immunobiology and tissue integrity both in the
stomach and in areas other than the gastrointestinal tract [21].
Herein, we demonstrate that H. pylori L-asparaginase plays a
major role in cell-cycle inhibition induced by BCF on cultured
cells, that inhibition of proliferation is more pronounced in cells
with low expression levels of the enzyme asparagine synthetase
and that L-asparaginase can stimulate the immune response in
infected patients.
Results
Identification of cell-cycle inhibiting activity in H. pylori
BCF
BCF from H. pylori CCUG 17874 typically inhibited 5-bromo-
29-deoxy-uridine (BrdU) incorporation of normal human diploid
cells (HDF) by 39.9623.1% (n=61, P,10
227). A typical elution
profile of BCF obtained by size-exclusion chromatography on a
Hi-Load Superdex 75 column is represented in Fig. 1A (black
line). Active fractions inhibited BrdU incorporation by HDF cells
(Fig. 1A, grey histograms) and showed compromised BrdU
incorporation between 15.068.1 and 41.664.0% versus untreated
control (100% BrdU incorporation). Separation of active fractions
on a non-reducing sodium dodecyl sulphate (SDS)-PAGE (Fig. 1B)
gave only 4 silver-stained bands of different molecular masses with
Figure 1. Isolation of the cell-cycle inhibiting activity from BCF. (A) Elution profile of BCF (black line) and cell-cycle inhibiting fractions
identified by BrdU incorporation in HDF cells (grey histograms). (B) Active fractions separated on a non-reducing SDS gel. The four silver-stained
bands of different molecular weights analysed by LC-MS/MS are in rectangles. (C) Stacked line representation of the relative intensities displayed by
each of the bands detected in SDS-PAGE in (B). Numbers correspond to molecular masses in kDa. (D) L-asparaginase activity of cell-cycle inhibiting
fractions.
doi:10.1371/journal.pone.0013892.g001
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activity (Fig. 1C and Supplementary Fig. S1). Analysis of these
bands by LC-MS and MS-MS revealed multiple proteins (Table 1),
with their N-terminal sequences confirmed in several cases (data
not shown). With the exception of c-glutamyltranspeptidase
(GGT) and L-asparaginase, detected in the bands corresponding
to approximately 15 and 121 kDa, respectively, no other homo-
logues of the other proteins found have been reported to interfere
with the cell cycle. GGT (locus tags HP1118 in the H. pylori 26695
genome) is responsible of cell-cycle inhibition in T-cells [24] and
in AGS cells [25]. The expected molecular mass of this protein
in native conditions is 60 kDa, but a fragment with a molecular
mass of 13.3 kDa and corresponding to residues 448–564 was
previously isolated by 2D electrophoresis and peptide fingerprint-
ing in the H. pylori secretome [26]. Our MS data are compatible
with the predicted tryptic peptides derived from this fragment
(49.6% coverage) and indicate that the latter is likely to exist as an
independent unit whose significance is thus far unknown. L-
asparaginase (locus tag HP0723, ‘‘probable asparaginase by
sequence similarity’’), belongs to an important family of related
amidohydrolases that catalyse the deamidation of L-asparagine
(Asn) [27]. The molecular mass of a single subunit is 37 kDa, but,
being in the absence of denaturation, the enzyme was correctly
detected in its tetrameric functional form (theoretical MW
144 kDa). Cells lacking a functional asparagine synthetase and
exposed to L-asparaginase undergo cell-cycle arrest in G1 and, in
some cases, such as Acute Lymphatic Leukemia (ALL), die by
apoptosis [28]. These features prompted us to investigate whether
GGT and L-asparaginase were involved in this process.
GGT is not responsible for HDF cell-cycle inhibition
GGT activity of BCF was approximately 0.006 U/ml and was
totally inhibited by the GGT specific inhibitor acivicin (ACI)
(Table 2). Despite this, the capability of BCF to affect BrdU
incorporation by HDF cells following GGT inhibition was un-
altered (Fig. 2A, P,0.05 versus uninoculated broth culture filtrate,
UBF). This demonstrated that GGT was not involved in the effect
on the cell cycle we observed. The disagreement between the
results reported in T-lymphocytes and AGS cells [24,25] on one
side, and our data on the other underline the importance of the
specific cell lineage investigated and suggests that a single bacterial
factor can have different effects on different cells types. Also, the
lack of inhibition by DON, a well known inhibitor of GGT activity
along with acivicin, might indicate a specific feature of the catalytic
site. GGT activity of BCF derived from both G27 and G27 ansB
-
strains averaged at 0.0005 U/ml.
L-asparaginase activity is a common feature of H. pylori
strains
Chromatographic fractions with cell-cycle inhibiting activity
showed an L-asparaginase activity ranging from 0.075 to 0.4 U/ml,
(Fig.1D),andshoweda profileconsistentwith thatobservedforcell-
cycle inhibition (Fig. 1A). BCF produced with the CCUG 17874
strain possessed an L-asparaginase activity with a typical activity of
0.021 U/ml. This was found to be a common feature of H. pylori
strains: the measured activity was approximately 0.100 U/ml for
BCF derived from the G27 strain, 0.029 U/ml for the G21 strain
and 0.027 U/ml for the 60190 strain.
The specific inhibitor DONV inhibits L-asparaginase
activity and affects BCF inhibition of the cell cycle
An L-asparagine mimic (5-diazo-4-oxo-L-norvaline, DONV),
and the diazo analogue of L-glutamic acid 6-diazo-5-oxo-L-
norleucine (DON) are known to act as specific suicidal inhibitors of
glutaminase-asparaginases, and have been used in a variety of
applications including the labelling of active sites [29]. BCF
exposed to DONV showed an average reduction of L-asparagi-
nase activity of 76.2% (0.005 U/ml versus 0.021 U/ml, Table 2)
and BrdU incorporation of HDF cells incubated with DONV-
treated BCF returned to values comparable to the control (Fig. 2A,
P.0.05). A similar result was observed with BCF pre-incubated
with both DONV and acivicin (Fig. 2A, P.0.05). Concentrations
of DONV similar to those expected after its removal by
diafiltration did not interfere with the cell cycle (data not shown).
DON caused no significant reduction of L-asparaginase activity
(0.016 U/ml versus 0.0021 U/ml, Table 2). These results
demonstrate that L-asparaginase is involved in cell-cycle inhibition
induced in HDF cells by H. pylori BCF. Furthermore, the
differential effect of the inhibitors DON and DONV suggests a
catalytic site with a strong preference for L-asparagine rather than
L-glutamine.
BCF from a G27 ansB
- mutant lacks L-asparaginase
activity and displays reduced cell-cycle inhibiting activity
Mutagenesis experiments aimed at producing CCUG 17874
strains lacking L-asparaginase were unsuccessful. As an alternative,
a mutant was generated in the G27 strain whose ansB gene
(HPG27_679) had been previously isolated and which shows close
homology with the CCUG 17874 ansB gene (HP0723) [30]
(Supplementary Fig. S2). BCF derived from the ansB
- G27 strain
had no L-asparaginase activity (0.060.001 U/ml) and showed a
BrdU incorporation similar to the control (P.0.05), while the
wild-type G27 and CCUG strains had a BrdU incorporation
reduced by 22.764.2% and 19.063.1%, respectively (both with
P,0.05 versus UBF, Fig. 2B). Thus, the G27 knockout strain
Table 1. Mass spectrometry data.
MW
610
3
Locus
tag Protein name
121 HP0723
HP0875
HP0011
jhp11044
jhp1290
L-Asparaginase
Catalase
Chaperonin
Purine nucleoside phosphorylase deoD-type
(3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase
37 HP1563
HP0736
HP0011
jhp0098
jhp0673
Peroxiredoxin
Aminotransferase
Chaperonin
Cystathionine gamma-synthase
Aminotransferase
24 HP1178 Purine nucleoside phosphorylase deoD-type
15 HP1118 Gamma-glutamiltranspeptidase fragment
doi:10.1371/journal.pone.0013892.t001
Table 2. GGT and L-asparaginase activity.
BCF ACI DON DONV
GGT (U/ml) 0.006 0.000* 0.006 N.D.
L-asparaginase (U/ml) 0.021 0.019 0.016 0.005*
BCF: Broth Culture Filtrate; ACI: acivicin; DON: 6-diazo-5-oxo-L-norleucine
DONV: 5-diazo-4-oxo-L-norvaline; GGT: c-glutamyltranspeptidase; SD#11%; *:
P,0.05 versus BCF.
doi:10.1371/journal.pone.0013892.t002
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inhibiting activity by the corresponding BCF.
Cells sensitive to BCF are also sensitive to recombinant
H. pylori L-asparaginase
In a previous study we described the production, biochemical
characterisation and cytotoxicity of recombinant H. pylori L-
asparaginase [31]. Now, we report that the recombinant enzyme,
a type II L-asparaginase [32,33], shows a strong preference for L-
asparagine over L-glutamine, with a broad pH optimum activity in
the range 7.0–10.0 and a drop of 80% activity below pH 4.0 [31]
The H. pylori enzyme displayed a cytotoxic activity towards HDF
cells and several tumour cell lines consistently higher than the E.
coli orthologue, affecting survival in a concentration and cell-type
dependent manner [31].
Along these lines, we initially investigated the inhibitory activity
of recombinant L-aparaginase on cell-cycle, monitoring BrdU
incorporation into HDF cells at different enzyme concentrations.
The enzyme caused an inhibition of cell-cycle of 23.4613.8% at
0.01 U/ml and 28.969.9% at 0.1 U/ml (n$3, P,0.01) (Fig. 2C),
which confirmed that more than 50% of the effect exerted by BCF
(39.9623.1%, range: 16.8–63.0%) could indeed be ascribed to L-
asparaginase. We then investigated the activity of the recombinant
H. pylori enzyme on the cell-cycle of a group of tumoral gastric cell
lines with different levels of differentiation (AGS, MKN28,
MKN74, MKN7) and compared the effects with those exerted
by the E. coli enzyme (Fig. 3A and 3B, respectively). All the cell
lines exposed to H. pylori L-asparaginase showed a stronger cell-
cycle inhibition than when exposed to comparable concentrations
of the E. coli enzyme (Fig. 3C), with MKN7 and MKN28
displaying an IC50 difference of nearly 2 orders of magnitude.
MKN74 was the less affected by both enzymes.
Cell-cycle inhibition induced by L-asparaginase is related
to the expression levels of asparagine synthetase
We then evaluated the relationship between asparagine syn-
thetase expression and cell-cycle inhibition. For this, a Western
blot analysis was performed for asparagine synthetase in the cell
lines under examination (Fig. 4A). AGS, MKN7 and MKN28 cells
expressed twice the amount, and MKN74 cells 3 times the amount
of asparagine synthetase with respect to HDF cells (Fig. 4B). These
expression levels were inversely related to cell-cycle inhibition
induced by BCF [21] and by both E. coli and H. pylori recombinant
L-asparaginases (Fig. 3C), with the notable exception of MKN7
and MKN28 for H. pylori L-asparaginase. While the former
correlation is well documented, the latter exception might be
related to their different genotype (Supplementary Table S2).
Sub-cellular localisation of L-asparaginase in H. pylori
CCUG 17874
Sub-cellular fractions of H. pylori were prepared as reported in
the Materials and Methods section. The purity of subcellular frac-
tions was assessed by measuring the activities of marker enzymes.
Catalase, carbonic anhydrase (CA) and malonate dehydrogenase
(MDH) were found in the expected H. pylori subcellular fractions:
Figure 2. Cell-cycle inhibition in HDF cells. BrdU incorporation
in HDF cells incubated with: (A) UBF and BCF treated with the L-
asparaginase inhibitor 5-diazo-4-oxo-L-norvaline (DONV, 20 mM) or the
GGT inhibitor acivicin (ACI, 5 mM), (B) UBF and BCF derived from
different H. pylori strains, (C) different concentrations of recombinant
L-asparaginase. Resultsare expressed as a mean 6 SDfrom 5 independent
experiments.
*P#0.05,
**P#0.01.
doi:10.1371/journal.pone.0013892.g002
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PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e13892periplasm [34], spheroplast [35] and cytoplasm [36], respectively
(Fig. 5C). As expected, no activity of CA was found in the pre-lytic
fraction. A significant level of cross-contamination was only
observed between the periplasmic and spheroplast soluble fraction
(about 25%, 2 and 3 in Fig. 5C), which means that L-asparaginase
amounts detected in the corresponding fractions might differ by
this percentage. Equivalent amounts of proteins from all the
subcellular fractions were analysed by Western blot to localise L-
asparaginase. The total L-asparaginase activity of each fraction
was also determined. Two L-asparaginase forms with different
molecular masses were identified in the periplasm and in the
spheroplast soluble and insoluble fractions (Fig. 5A, lanes 2, 3 and
4). The higher molecular mass form (approximately 39 kDa) was
less represented (40%) than the lower one (about 37 kDa, 60%).
Figure 4. Expression of asparagine synthetase in cultured cell
lines. (A) Western blot analysis of HDF, AGS, MKN28, MKN7 and MKN74
cell lysates for asparagine synthetase (AS). Actin was determined as
loading control. (B) Densitometric analysis of protein levels normalized
to the internal loading control. Results are expressed as a mean 6 SD
from 3 independent experiments
*P#0.05,
**P#0.01.
doi:10.1371/journal.pone.0013892.g004
Figure 3. Cell-cycle inhibition by L-asparaginase. BrdU incorpo-
ration in cell lines exposed to variable concentration of recombinant H.
pylori CCUG 17874 (A) and E. coli L-asparaginase (B) compared to
untreated control cells. Boxes: magnification of the corresponding chart
for L-asparaginase activities lower than 0.5 U ml
21. The points represent
means (n$3); SD not represented for clarity. (C) IC50 (L-asparaginase
concentration inducing 50% cytotoxicity in U ml
21)o fH. pylori and
E. coli L-asparaginase (MTT assay).
doi:10.1371/journal.pone.0013892.g003
H. pylori L-Asparaginase
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approximate molecular mass calculated for the cleavable signal
sequence predicted by the programs SignalP 3.0 [37] and
PSORTb [38]. Interestingly, the pre-lytic fraction included mainly
the 37 kDa-form (Fig. 5A, lane 1), suggesting that, in appropriate
conditions, this form of the enzyme is free to leak through the
outer bacterial membrane, while the 39 kDa-form might be
membrane associated, as predicted by the BII server (http://
protein.bii.a-star.edu.sg/sgi-bin/localization/gram-negative). It is
also worthwhile noting that enzyme activity showed a progressive
increase going from the cytoplasm to the periplasmic space
(Fig. 5B). This supports the hypothesis of a maturation of the
enzyme during its progress towards the latter. All this evidence,
along with its presence in BCF, suggests that L-asparaginase can
reach the external microenvironment, and therefore the host, in a
process likely to involve a secretion system.
ELISA assays
To determine whether H. pylori L-asparaginase is immunogenic
in humans, we developed a H. pylori specific ELISA assay. Nearly
21% (9/43) of patients positive on the Helicobacter pylori IgG test
(commercial kit 1, gold standard for the identification of previous
or ongoing bacterial infection) were also positive for anti-L-
asparaginase IgG, thus indicating that the protein causes an
immune response in a subset of hosts (Fig. 5D). We found a lower
IgG concentration for L-asparaginase as compared to commercial
kit 1 (44.8617.5 versus 148.5695.5 U/ml) (Fig. 5D) and suspect
that this is due to the multiple antigens used in the latter.
Intriguingly, we found that 6 out of 43 patients negative by
commercial kit 1 (14%) were positive for the L-asparaginase-based
ELISA (Fig. 5E). This was not due to cross-reactivity since none of
these patients were positive to E. coli L-asparaginase. Moreover, all
of them were positive for H. pylori when commercial kit 2 was
employed, suggesting that the antibodies detected were specific for
H. pylori L-asparaginase and that this novel antigen may have a
potential diagnostic application. Future work in our laboratory will
seek to clarify this.
Discussion
This work builds on our previous findings [21] on the cell-cycle
inhibiting effect of H. pylori BCF on HDF and epithelial cell lines
derived from human gastric tumours with different levels of
differentiation (AGS, MKN28, MKN74 and MKN7), and focuses
on the isolation and characterisation of L-asparaginase as the
factor responsible for cell-cycle inhibition.
L-asparaginases (EC 3.5.1.1) are amidohydrolases that primarily
catalyse the conversion of L-asparagine to L-aspartate and
ammonia. Bacterial asparaginases are 140–150 kDa tetramers
[39] built of identical subunits of 300–350 amino acid residues
each, and include four independent catalytic sites [39,40]. Some of
them, especially the E. coli enzyme, display anti-leukemic activity,
which has been primarily attributed to the reduction of L-
asparagine in blood [41,42].
Our genetic and functional characterisation of H. pylori CCUG
17874 L-asparaginase [31] led us to identify that the ansB gene,
which consists of 993 bp (330 residues), shows a good homology to
other H. pylori strains at the nucleotide, amino acid sequence and
secondary structure level (Supplementary Fig. S2). As the activity
of the recombinant enzyme steadily increases along the pH
gradient observed throughout the gastric mucus layer (2.25–6.96)
[43], a peak of activity is likely to occur in vivo at the epithelial
surface. In this respect, previous work has showed that L-
asparaginase is, in fact, an acid-inducible gene [30] and a virulence
factor [44].
Following exposure to H. pylori BCF, HDF, MKN7 and
MKN28 cells showed a significant increase in the number of cells
in G1 phase, and, concomitantly, a decrease in those in the S
phase [21]. In AGS cells, BCF induced a modest increase in
the number of cells in G1 phase (by about 16%), without any
significant decrement in S phase compared to controls [21]. No
effect was observed on the cell cycle of the MKN74 cell line [21].
Similar changes in BrdU incorporation were observed when
purified L-asparaginase was examined. In all cases, the E. coli
enzyme appeared to be less active than the H. pylori one.
Previous studies have shown that treatment of leukemic cells with
E. coli L-asparaginase causes arrest in the G1 phase [28,45] and
triggers the apoptotic pathway. However, L-asparaginase may also
cause toxicity without inducing programmed cell death [46–49].
The factors leading to these alternative effects are not yet known.
The mechanism of action of bacterial L-asparaginases seems to
depend on their capability to reduce the levels of L-asparagine, for
which some cell-types are auxotrophes. In fact, the cell-cycle block
of cell clones, especially leukemic, exposed to this enzyme class has
been previously described to depend on the expression level of
asparagine synthetase [50]. A similar correlation is present in the
cell lines we tested to recombinant H. pylori L-asparaginase.
Interestingly, MKN7 and MKN28 cells represent an unexpected
exception: they express relatively high levels of asparagine
synthetase but at the same time their cell-cycle is strongly inhibited
by H. pylori L-asparaginase. High expression of asparagine
synthetase might be related to their carrying a mutant p53, a
possible transactivator of the asparagine synthetase gene (http//
atlasgeneticsoncology.org/Genes/ASNSID44323ch7q21.html), while
the relatively high sensitivity of their cell-cycle to L-asparaginase might
depend on the lack of p21
WAF1/CIP1, that might thus act as a resistance
barrier. p15 and p16, absent in MKN28 but present in MKN7, do not
seem to significantly affect BrdU incorporation. Cyclin E is absent in
MKN74 cells and, interestingly, proliferation of these cells is not
inhibited by BCF or L-asparaginase. All this evidence suggests that
cell-cycle proteins might have a pivotal role in mediating L-
asparaginase effects and suggest the need for further investigations.
Along this line, we speculated that a different status of the L-
asparagine synthesis pathway in different cell types of the gastric
epithelium could condition their response to bacterial L-asparag-
inase. In fact, preliminary immunohistochemistry data of human
acido-peptic mucosa demonstrate an unequal expression of
asparagine synthetase throughout the gastric epithelium, with a
Figure 5. Subcellular localisation of L-asparaginase and ELISA assays. (A) Western blot performed on 100 mg of the subcellular fractions of
H. pylori CCUG 17874 with an anti-asparaginase antibody. From left to right: 1: pre-lytic fraction; 2: periplasmic fraction; 3 and 4: soluble and insoluble
spheroplast fractions, respectively. Molecular mass markers (kDa) are indicated. (B) Total L-asparaginase activity associated with each fraction (U). (C)
Catalase, carbonic anhydrase (CA) and malonate dehydrogenase (MDH) were found in the expected H. pylori subcellular fractions: periplasm (2)[34],
spheroplast (3) [35] and cytoplasm (4) [36], respectively. (D) Scatter-plot of ELISA assay results on sera from 42 H. pylori positive and 43 H. pylori
negative patients. Serum samples (1:101 dilution) were tested in parallel using commercial kit 1 and plates pre-coated with recombinant H. pylori L-
asparaginase. Medians indicated as horizontal bars. 21% of the total samples were anti-L-asparaginase IgG positive (+). (E) Comparison of the results
obtained with commercial kit 1 and L-asparaginase-based ELISA.
doi:10.1371/journal.pone.0013892.g005
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neck cells (Supplementary Fig. S3). Inhibition of cell-cycle of cells
lacking asparagine synthetase could favour the proliferation of
those carrying the enzyme, thus becoming more suitable to
overcome the action of an L-asparagine deficiency. Thus, though
the main mechanism of action of H. pylori L-asparaginase is
expected to be its contribution to buffer the acidic microenviron-
ment of the stomach through ammonia production, similarly to
urease, during the process of in vivo colonisation, it could also
interfere with the cell cycle of the epithelium altering the normal
balance between proliferation and apoptosis.
Contact between L-asparaginase and the host requires the
release or secretion of the enzyme to the external environment. In
good agreement with this idea, our data show that the highest
enzyme activity was detected in the most external subcellular
bacterial fraction although its presence was ubiquitous. This, along
with the observation that the protein has a predicted signal
peptide, suggests that protein transit into the external environment
might occur through secretion or through release of outer
membrane vesicles [51], leading to immune stimulation of the
host and the production of specific IgGs. We have demonstrated
that these antibodies allow detection of infected patients otherwise
undetectable by one of the available commercial kit.
In conclusion, the present work shows that H. pylori L-
asparaginase is a relevant actor in cell-cycle inhibition and a
promising diagnostic tool. Its role as a potential pathogenic factor
will now be thoroughly analysed both by direct administration of
the protein to animal models and by analysing its internalisation in
cells of infected patients.
Materials and Methods
Ethics statement
At the time this study was performed, Institutional Ethical
Boards in Italy were devoted only to the regulation, authorisation
and monitoring of pharmaceutical studies and not of medical
devices, including new reagents for in vitro diagnosis. Patients with
gastric symptoms who had to undergo blood sample testing were
however asked to sign a written informed consent form at the
Centro Analisi Monza (CAM, Monza, Italy). Mice immunization
was conducted according to the guidelines of the European
Communities Directive 86/609/EEC regulating animal research
and following a protocol approved by the Ministry of Health (n.
10169321466.9) in accordance with national laws.
Bacterial strains and broth culture filtrate (BCF)
production
We used urease positive, VacA
+, CagA
+ H. pylori strains CCUG
17874 (Culture Collection University of Goteborg, Goteborg,
Sweden), 60190 (ATCC 49503), G21 and G27, and the urease-
positive, VacA
-, CagA
- G21 H. pylori strain (kindly provided by N.
Figura, Siena, Italy).
For routine culture, the bacterial broth culture filtrate (BCF)
and Uninoculated Broth culture Filtrate (UBF) were produced in
brucella broth (Difco, Detroit, MI) supplemented with 5%
inactivated foetal bovine serum (FBS, Invitrogen, Milan, Italy),
Skirrow and Vitox (Oxoid, Basing-stoke, UK) as described [21].
For biochemical studies, the CCUG 17874 strain was initially
cultured as above until the OD450 reached 1.0 Absorbance Units
(AU). Brucella broth was gradually replaced by F10 (Invitrogen,
Milan, Italy) by subsequent two-fold dilutions. The culture
medium was then removed by centrifugation and bacteria
resuspended in an equal volume of F10 supplemented with
Skirrow, Vitox and 200 mg/ml b-cyclodextrin [52]. As the cell
culture was viable for 7 d in these conditions, BCF was consistently
prepared on day 6.
Preparation of H. pylori G27 DHP0723::KanSacB, KanR,
Sucrose Sensitive mutant
A G27 DHP0723::KanSacB, KanR, Sucrose Sensitive mutant
was prepared using the primers of Supplementary Table S1. A
portion of the N-terminal and C-terminal regions of the ansB gene
(HPG27_679) were amplified and fused together using Splicing by
Overlap Extension (SOE) PCR. This strategy deleted the internal
portion of the gene and added an Xho I and Sma I site for cloning
of the KanSacB cassette from pKSF-II. The SOE reaction was
conducted in a series of 3 PCR reactions. In the first, the ansB-
Forward 1 and ansB-Reverse 1 PCR primers were used to amplify
the N-terminal region of ansB from G27. In the next round, ansB-
Forward 2 and ansB-Reverse 2 were used to amplify the C-
terminal region of ansB. These products were purified, mixed and
the SOE reaction performed using the ansB-Forward 1 and ansB-
Reverse 2 primers. This PCR product was then subcloned into
pGEMT-Easy and the proper insert verified by EcoR I, Xho I and
Sma I digestion. This plasmid was subsequently digested with Xho I
and Sma I and the KanSacB fragment from pKSF-II, which was
obtained by similar digestion, was ligated to the ansB deletion
construct. The resulting verified plasmid was transformed into
G27 and transformants were selected on Kan 25. The resulting
isolate was analyzed with the ansB-Rev-Far downstream primer
that lies outside of all of the primers used to make the mutation
construct along with the sacBSCN-F2 primer to ensure proper
insertion of the cassette into the chromosome. Additionally, the
PCR product was sequenced.
Cell lines and culture conditions
Normal human diploid embryonic fibroblasts (HDF, kindly
donated by J. Sedivy, Brown University Providence, RI) and
epithelial cell lines derived from human gastric tumours with
different levels of differentiation (AGS [53], MKN28, MKN74,
MKN7 [54]) were routinely grown at 37uC in E-MEM (HDF),
RPMI 1640 (AGS) and DMEM/Ham’s nutrient mixture F-12
(MKN7, MKN28, MKN74) containing 100 IU ml
21 penicillin
and 100 mgm l
21 streptomycin, and supplemented with 10% FBS,
in a 5% CO2 humidified atmosphere. Cells were used in
exponential growth throughout all the experiments.
5-Bromo-29-deoxy-Uridine assay
For routine assay of cell-cycle progression, cells were seeded in
96-well microtitre plates at 4610
3 cells/well in a final volume of
100 ml medium. After 24 h growth, treatments were performed on
subconfluent cell monolayers in 150 ml volumes per well and
incubated at 37uC for 24 h. Progression throughout the S phase
was measured with the 5-Bromo-29-deoxy-Uridine Labelling and
Detection kit III (Roche Applied Biosciences, Mannheim,
Germany) by incubating the samples in the presence of 10 mM
5-bromo-29-deoxy-uridine (BrdU) for the last 2 h of treatment.
Size exclusion chromatography
For isolation of the cell-cycle inhibiting factor, one litre of BCF
derived from an H. pylori CCUG 17874 culture in F10 medium
was concentrated to 10 ml with a 10 kDa cut-off concentrator and
loaded onto a Hi-Load 26/60 Superdex 75 column (GE
Healthcare Europe GmbH, Milan, Italy) equilibrated in 60 mM
Tris-HCl, pH 8.0, 100 mM NaCl, using an Amersham FPLC
system. Elution was performed at 3 ml/min with equilibration
buffer and spectrophotometrically monitored at 280 nm. Three ml
H. pylori L-Asparaginase
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inhibiting activity using the BrdU assay. Twenty ml of each active
fraction were analysed by a 12% SDS-PAGE after mixing with
10 ml 65 mM Tris-HCl, pH 7.5, 1% SDS, 10% glycerol, 0.02%
bromophenol blue as a non-reducing buffer. To increase sensi-
tivity, after Coomassie staining, the gel was silver stained as
described by Hochstrasser [55].
Liquid chromatography-mass-spectrometry (LC-MS) and
MS-MS
Two hundred ml of each active fraction were concentrated 10
times using a 10 kDa cut-off concentrator, and loaded on a 10%
SDS-PAGE in non-reducing conditions. After Coomassie-staining,
bands whose intensity staining profiles matched the profile of cell-
cycle inhibiting activity were cut from the gel and processed for
subsequent trypsin digestion and liquid chromatography-mass-
spectrometry (LC-MS/MS) analysis on a Q-ToF Ultima Global
(Micromass, Waters), with an ESI source coupled with an online
nano-HPLC [56]. The results were analysed using the Mascot
software (http://www.matrixscience.com).
Enzymatic assays
c-glutamyltransferase (GGT) was assayed with an enzymatic
colorimetric assay in which the enzyme transferred the glutamyl
group of L-c-glutamyl-3-carboxy-4-nitroanilide to glycyl-glycine
[57]. One Unit is defined as the amount of enzyme that catalyzes
the transformation of one micromole of substrate per min at 37uC.
L-asparaginase activity was measured by a stopped assay using
Nessler’s reagent [27], or, alternatively, by the MAAT Asparag-
inase activity test (Medac, Wedel, Germany). One unit is the
amount of enzyme catalysing the production of 1 mmol of ammonia
per min at 37uC. The changes in the slope of time-dependent
reduction in hydrogen peroxide absorbance at 240 nm (PBS,
pH 7.2) were used as a measure of catalase activity and were
calculated according to the method of Beers & Sizer [58]. One unit
of catalase activity decomposes 1 mmol hydrogen peroxide at
240 nm per min at a substrate concentration of 10 mM. MDH and
CA activities were assayed spectrophotometrically [59,60]. For
MDH, one unit is defined as the amount of enzyme that will oxidize
1.0 mmol NADH per min at 25uC, pH 7.5. For CA, one unit will
causethe pHof a 0.012 M buffer to drop from 8.3to6.3perminute
at 0uC.
Enzymatic inhibition assays
BCF was mixed with an equal volume of PBS (control) or of
one of the following: 40 mM solutions in PBS of the specific
asparaginase inhibitors 6-diazo-5-oxo-L-norleucine (DON, the
diazo analogue of L-glutamic acid) or 5-diazo-4-oxo-L-norvaline
(DONV, an asparagine analogue), kindly donated by Prof.
Pizzorno (University of Yale), ora 10 mM solution in PBS of the
specific GGT inhibitor acivicin. Samples were incubated at room
temperature for 16 h. L-asparaginase activity was measured with
the MAAT activity test. They were then dialysed by diafiltration in
10 kDa cut-off concentrators until the concentration of inhibitors’
was ,1 nM. Inhibition of BrdU incorporation was then evaluated
in HDF cells.
H. pylori fraction preparation
The cell pellet obtained from a H. pylori CCUG 17874 50 ml
culture was washed in 10 ml PBS, resuspended in 1.5 ml of
10 mM Tris-HCl pH 7.6, 20% sucrose and, after a 5 min
incubation on ice, mixed with 50 ml of 0.5 M EDTA, pH 8.0.
After a 10 min incubation and subsequent centrifugation, the
supernatant containing proteins that leaked from the cells or were
located at or near the cell surface was collected (fraction 1 or pre-
lytic), whereas cells were converted into spheroplasts by resus-
pending them in 1 ml cold distilled water and incubating on ice for
10 min. After centrifugation, the supernatant (periplasmic frac-
tion, fraction 2) was collected, whereas the spheroplasts were
resuspended in 500 ml of 1 M Tris- HCl, pH 7.6, incubated on ice
for 30 min and centrifuged. The supernatant (spheroplast soluble
fraction, fraction 3) was recovered and the pellet (spheroplast
insoluble fraction, fraction 4) resuspended in 500 mlo f5 0m M
Tris-HCl, pH 8.0, 2 mM EDTA, 0.1 mM DTT, 5% (v/v)
glycerol.
Production of recombinant H. pylori CCUG 17874
L-asparaginase
Recombinant L-asparaginase from H. pylori CCUG 17874 was
produced in Escherichia coli BL21(DE3) cells harbouring construct
pDC1 as described [31]. Activity was determined as described
above.
Production of a monoclonal anti-L-asparaginase
antibody
For antibody production, a 6-month-old mouse (C57/B) was
immunised once with 30 mg of recombinant H. pylori CCUG
17874 L-asparaginase supplemented with Complete Freunds
Adjuvant (Pierce, Rockford, IL), and twice with 20 mg of enzyme
supplemented with Incomplete Freunds Adjuvant (Pierce, Rock-
ford, IL) every 4 weeks. Antibody titre was analysed by direct
enzyme linked immunosorbent assay (ELISA). Spleen B cells were
fused with an equal number of NS0 mouse myeloma cells and, the
following day, the hybridomas seeded in petri dishes in selective
medium. An IgM antibody with good reactivity was then isolated
from 1l of the culture supernatants using Protein A Sepharose (GE
Healthcare, Europe GmbH, Milan, Italy) and subjected to
biotinylation with the FluoReporter Mini-Biotin-XX Protein
Labelling Kit (Molecular Probes, Invitrogen, Milan, Italy).
Western Blotting
Protein samples and molecular weight markers (Precision
Protein Standards, BioRad, Milan, Italy) were separated on a
12% SDS-PAGE in reducing conditions and transferred onto a
polyvinylidene difluoride membrane (Millipore, Billerica, MA).
The membrane was blocked with 5% (w/v) milk powder in PBS
containing 0.05% Tween (PBS-T). For analysis of the subcellular
localization of L-asparaginase, the membrane was incubated with
the biotinylated mouse monoclonal anti-L-Asparaginase antibody
at 1 mg/ml in PBS-T, 1% BSA for 1 h. Blots were washed 3 times
(5 min each) in PBS-T, incubated with a streptavidin-horseradish
peroxidase conjugate (GE Healthcare Europe GmbH, Milan,
Italy) in PBS-T for 45 min, washed 3 times as above, and
visualised by ECL (GE Healthcare Europe GmbH, Milan, Italy).
For analysis of the expression levels of asparagine synthetase in
mammalian cells, the membrane was incubated with a rabbit anti-
asparagine synthetase polyclonal antibody (Epitomics, Burlin-
game, CA) at a 1:5000 dilution in PBS-T, 1% BSA at room
temperature for 1 h. After 3 washes in PBS-T (5 min each), the
blot was incubated with a horseradish peroxidase conjugate anti-
rabbit antibody (GE Healthcare Europe GmbH, Milan, Italy) in
PBS-T for 45 min, washed 3 times, and visualised by ECL.
Mammalian cell lysis
For Western Blotting, AGS, MKN7, MKN28, MKN74 and
HDF cells, grown in 250 ml flasks, were lysed [61] and briefly
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12000 x g at 4uC for 30 min. Protein concentration of the
supernatant was determined with the MicroBCA protein assay
(Pierce, Rockford, IL). Aliquots containing 20 mg of proteins were
utilised immediately.
Enzyme-linked immunosorbent assay (ELISA)
In order to analyse patients’ immune response to L-asparaginase,
an ELISA assay was performed. Serum samples were collected and
tested using a Helicobacter pylori IgG Enzyme Immunoassay test
(commercial kit 1). 43 positive (IgG concentration.24 U/ml) and
42 negative (IgG concentration,20 U/ml) sera were then tested in
parallel with both commercial kit 1 and an Immulon 96-well plate
(Santa Cruz Biotechnology, Inc) pre-coated with H. pylori L-
asparaginase at a final concentration of 1 mg/ml in PBS overnight.
Samples which tested negative with the commercial kit and positive
by L-asparaginase ELISA were re-assayed with a second commer-
cial kit for Helicobacter pylori IgG (commercial kit 2).
Statistical analysis
Student’s t test was used for pairwise comparisons (n.10).
Kruskal-Wallis non-parametric test followed by Bonferroni-type
post-hoc analysis was used for multiple comparisons (n,10).
Results are reported as mean6SD and P,0.05 was considered
significant. IC50 (the L-asparaginase concentration inducing 50%
cytotoxicity) values were determined with the software BioDataFit
1.02, available at the URL: http://www.changbioscience.com/
stat/ec50.html
Supporting Information
Figure S1 Band intensities. Three-dimensional histogram rep-
resentation of the relative intensities displayed by each of the
bands detected in cell-cycle inhibiting fractions by SDS-PAGE.
On the x axis: molecular mass (kDa), on the y axis: relative
intensity (arbitrary units), on the z axis: elution volume (ml).
Found at: doi:10.1371/journal.pone.0013892.s001 (4.84 MB TIF)
Figure S2 L-asparaginase sequence alignment. (A) Amino acid
sequence alignment of L-asparaginase from different strains of H.
pylori: from top to bottom: strain CCUG 17874, J99, HPAG1 and
G27. Black boxes include conserved regions, white boxes sequence
differences. (B) A model of an L-asparaginase monomer, showing
its conserved secondary structure.
Found at: doi:10.1371/journal.pone.0013892.s002 (0.75 MB TIF)
Figure S3 Asparagine synthetase in the human stomach. (A)
Asparagine synthetase distribution in human stomach mucosa at
46magnification. Arrows indicate the basis of two positive glands.
(B) Negative control. Paraffin embedded archive material was
sectioned at 5 mm and stained with UltraVision LP Large Volume
Detection System HRP Polymer and DAB Plus Chromogen
(Thermo Fisher Scientific, Barrington, IL, USA). After depar-
affinization and rehydration, tissue sections were washed twice in
PBS and incubated in goat serum, washed 4 times in PBS and, to
reduce nonspecific background staining due to endogenous
peroxides, incubated in hydrogen peroxide for 10 min. Each
washing step was performed in PBS for 5 min and repeated 4
times. After washing, Ultra V Block was applied and incubated at
room temperature for 5 min. The slides were washed and
incubated overnight at room temperature in buffer with (sample)
or without (negative control) anti-Asparagine Synthetase Rabbit
Monoclonal Antibody (Epitomics) diluted 1:50. After washing, the
Primary Antibody Enhancer was added and incubated at room
temperature for 10 min. The slides were then washed and
incubated in HRP Polymer at room temperature for 15 min,
washed again and incubated with diaminobenzidine (DAB). Once
rinsed 4 times in water, the slides were mounted with DPX and
observed at an optical microscope (Eclipse, E400, Nikon).
Found at: doi:10.1371/journal.pone.0013892.s003 (3.69 MB TIF)
Table S1 Primers for the preparation of H. pylori G27Del-
taHP0723::KanSacB, KanR, Sucrose Sensitive mutant
Found at: doi:10.1371/journal.pone.0013892.s004 (0.01 MB
RTF)
Table S2 Expression of cell cycle proteins by cell lines used in
the present study
Found at: doi:10.1371/journal.pone.0013892.s005 (0.01 MB
RTF)
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